申请人:ELI LILLY AND COMPANY
公开号:EP0050503A1
公开(公告)日:1982-04-28
Compounds of the formula
and pharmaceutically acceptable non-toxic acid addition salts thereof, in which
R is hydrogen, methyl, or ethyl;
A is the residue of a D-amino acid selected from Ala, Abu, Nva, Val, Nle, Leu, Ile, Gly(Al), Gly(Cp), Met, Cys(Me), Met(O), Cys(Me) (0), Ser, Thr, and Hse;
R1 is hydrogen, C1-C3 primary alkyl, cyclopropylmethyl, allyl, or propargyl;
X is bromo, iodo, chloro, C1-C3 alkyl, trifluoromethyl, or C1-C2 alkoxy;
B is the residue of a D- or L-amino acid lacking its carboxyl moiety and selected from
Gly, Ala, Abu, Nva, Val, Nle, Leu, lie, Pgl, Cys(Me), Cys(Me) (0), Cys(Me) (02), Cys(Et), Cys(Et) (0), Cys(Et) (02), Met, Met(O), Met(O2), Eth, Eth(O), Eth(O2), Ser(Me), Ser(Et), Hse(Me), and Hse(Et) as well as any of such residues substituted at the amino nitrogen by a C1-C3 primary alkyl; Z is -CH2OR2,
in which R2 is hydrogen or C1-C3 alkyl; subject to the proviso that, when R1 is other than hydrogen, B is the residue of an amino acid that lacks substitution at the amino nitrogen; which are useful analgesic agents, are described.
式化合物
及其药学上可接受的无毒酸加成盐,其中
R 是氢、甲基或乙基;
A 是 D-氨基酸的残基,选自 Ala、Abu、Nva、Val、Nle、Leu、Ile、Gly(Al)、Gly(Cp)、Met、Cys(Me)、Met(O)、Cys(Me) (0)、Ser、Thr 和 Hse;
R1 是氢、C1-C3 伯烷基、环丙基甲基、烯丙基或丙炔基;
X 是溴、碘、氯、C1-C3 烷基、三氟甲基或 C1-C2 烷氧基;
B 是缺少羧基的 D-或 L-氨基酸的残留物,选自
Gly、Ala、Abu、Nva、Val、Nle、Leu、lie、Pgl、Cys(Me)、Cys(Me) (0)、Cys(Me) (02)、Cys(Et)、Cys(Et) (0)、Cys(Et) (02)、Met、Met(O)、Met(O2)、Eth、Eth(O)、Eth(O2)、Ser(Me)、Ser(Et)、Hse(Me) 和 Hse(Et) 以及在氨基氮处被 C1-C3 伯烷基取代的任何此类残基;Z 是-CH2OR2、
其中 R2 是氢或 C1-C3 烷基;但条件是,当 R1 不是氢时,B 是氨基酸的残基,该残基在氨基氮处没有被取代;这些都是有用的镇痛剂。